Emerging Molecular Therapies for the Treatment of Acute Lymphoblastic Leukemia

被引：1

作者：

Vasekar, Monali ^{[1
,2
]}

Allen, Joshua E. ^{[1
,2
]}

Joudeh, Jamal ^{[1
,2
]}

Claxton, David ^{[1
,2
]}

机构：

[1] Penn State Hershey Canc Inst, Dept Med Hematol Oncol, Hershey, PA 17033 USA

[2] Penn State Hershey Med Ctr, Hershey, PA 17033 USA

来源：

IMPACT OF GENETIC TARGETS ON CANCER THERAPY | 2013年 / 779卷

关键词：

ALL; CD20; Ofatumumab; Rituximab; Hyper CVAD; Anti-CD22; CD22; Epratuzumab; Anti-CD19; CD19; Blinatumumab; CD3; SAR3419; Cell death; Tubulin; Anti-CD52; CD52; Alemtuzumab; CART-19; Notch inhibitor; Aurora kinase inhibitor; mTOR inhibitor; Polo-like kinase inhibitor; MDM2; inhibitor; p53; MEK inhibitor; Proteasome inhibitor; Nucleoside analogue; Clofarabine; Forodesine; HDAC inhibitor; Demethylating agent; PROTEASOME INHIBITOR BORTEZOMIB; INOTUZUMAB OZOGAMICIN; PEDIATRIC-PATIENTS; RITUXIMAB-CHOP; HYPER-CVAD; PHASE-I; CHEMOIMMUNOTHERAPY; CHEMOTHERAPY; INDUCTION; CHILDREN;

D O I：

10.1007/978-1-4614-6176-0_16

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The improved molecular understanding of cancer initiation, progression, and therapeutic resistance has yielded several novel molecular events that are being targeted by emerging therapies. While the treatment of ALL is a success story in the pediatric population, achieving a sustained remission in the adult population remains an area of investigation. Nevertheless, certain therapies have significantly improved the overall survival for adult ALL patients that should continue to improve with the discovery of better molecular targets and targeted agents. Here, we discuss novel therapeutic options under clinical investigation for the treatment of Philadephia chromosome negative ALL including immunotherapy, monoclonal antibodies, and small molecules that may be used as single agent or adjuvant therapy in the management of adult ALL.

引用

页码：341 / 358

页数：18

共 59 条

[1] Mitotic mechanics: the auroras come into view [J].

Andrews, PD ;

Knatko, E ;

Moore, WJ ;

Swedlow, JR .

CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (06) :672-683

[2] A Phase II Study of Campath-1H in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia: A Children's Oncology Group Report [J].

Angiolillo, Anne L. ;

Yu, Alice L. ;

Reaman, Gregory ;

Ingle, Ashish M. ;

Secola, Rita ;

Adamson, Peter C. .

PEDIATRIC BLOOD & CANCER, 2009, 53 (06) :978-983

[3]

[Anonymous], ASH ANN M

[4] Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience [J].

Barba, Pere ;

Sampol, Antonia ;

Calbacho, Maria ;

Gonzalez, Jose ;

Serrano, Josefina ;

Martinez-Sanchez, Pilar ;

Fernandez, Pascual ;

Garcia-Boyero, Raimundo ;

Bueno, Javier ;

Maria Ribera, Josep .

AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (06) :631-634

[5] SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies [J].

Blanc, Veronique ;

Bousseau, Anne ;

Caron, Anne ;

Carrez, Chantal ;

Lutz, Robert J. ;

Lambert, John M. .

CLINICAL CANCER RESEARCH, 2011, 17 (20) :6448-6458

[6] Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A pediatric oncology group study [J].

Borowitz, MJ ;

Shuster, J ;

Carroll, AJ ;

Nash, M ;

Look, AT ;

Camitta, B ;

Mahoney, D ;

Lauer, SJ ;

Pullen, DJ .

BLOOD, 1997, 89 (11) :3960-3966

[7] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[8] Phase I study of bortezomib in refractory or relapsed acute leukemias [J].

Cortes, J ;

Thomas, D ;

Koller, C ;

Giles, F ;

Estey, E ;

Faderl, S ;

Garcia-Manero, G ;

McConkey, D ;

Patel, G ;

Guerciolini, R ;

Wright, J ;

Kantarjian, H .

CLINICAL CANCER RESEARCH, 2004, 10 (10) :3371-3376

[9]

Cortes-Franco J., 2009, Blood, V114

[10] The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells [J].

de Vries, J. F. ;

Zwaan, C. M. ;

De Bie, M. ;

Voerman, J. S. A. ;

den Boer, M. L. ;

van Dongen, J. J. M. ;

van der Velden, V. H. J. .

LEUKEMIA, 2012, 26 (02) :255-264

← 1 2 3 4 5 6 →